1. Regorafenib as treatment for patients with advanced hepatocellular cancer
- Author
-
Krishnie Srikandarajah, Paul Ross, and Kiruthikah Thillai
- Subjects
Sorafenib ,Oncology ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Pyridines ,Angiogenesis Inhibitors ,Antineoplastic Agents ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacokinetics ,Regorafenib ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,In patient ,Neoplasm Staging ,Clinical Trials as Topic ,Hepatocellular cancer ,business.industry ,Phenylurea Compounds ,Liver Neoplasms ,General Medicine ,medicine.disease ,digestive system diseases ,Treatment Outcome ,Tolerability ,chemistry ,030220 oncology & carcinogenesis ,Pharmacodynamics ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Hepatocellular carcinoma is one of the fastest growing causes of cancer-related mortality worldwide. Sorafenib was the first and only drug to improve survival for patients with advanced disease, and has been the cornerstone of treatment for nearly a decade. Regorafenib is a multikinase inhibitor that has recently been shown to significantly improve survival in patients who have progressed on first-line sorafenib. In this review, we discuss the pharmacokinetic and pharmacodynamics properties of regorafenib and its efficacy and tolerability in patients with advanced hepatocellular carcinoma.
- Published
- 2017